Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3038819 | 1.00 | CA1 (0.46) | CA1CA2CA4ALDH1A1SLC18A3 | |
| SCHEMBL4613757 | 1.00 | CA1 (0.46) | CA1CA2CA4ALDH1A1SLC18A3 | |
| SCHEMBL21757863 | 1.00 | CA1 (0.46) | CA1CA2CA4ALDH1A1SLC18A3 | |
| SCHEMBL7733797 | 1.00 | CA1 (0.46) | CA1CA2CA4ALDH1A1SLC18A3 | |
| SCHEMBL8161261 | 1.00 | CA1 (0.46) | CA1CA2CA4ALDH1A1SLC18A3 | |
| SCHEMBL712232 | 1.00 | CA1 (0.46) | CA1CA2CA4ALDH1A1SLC18A3 | |
| SCHEMBL13767450 | 1.00 | CA1 (0.46) | CA1CA2CA4ALDH1A1SLC18A3 | |
| SCHEMBL23240064 | 0.97 | CA1 (0.43) | CA1CA2CA4ALDH1A1SLC18A3 | |
| SCHEMBL15178081 | 0.97 | CA1 (0.43) | CA1CA2CA4ALDH1A1SLC18A3 | |
| Methane SCHEMBL22471700 | 0.97 | CA1 (0.43) | CA1CA2CA4ALDH1A1SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115169-B2 | Method of treating tumors | LYTIX BIOPHARMA AS (NO) | 2015-08-25 | — | — | US | disclosed |
| US-9109048-B2 | Inhibition of tumor growth | LYTIX BIOPHARMA AS (NO) | 2015-08-18 | — | — | US | disclosed |
| US-20140037657-A1 | INHIBITION OF TUMOR GROWTH | LYTIX BIOPHARMA AS (NO) | 2014-02-06 | — | — | US | disclosed |
| US-8283315-B2 | Inhibition of tumour growth | LYTIX BIOPHARMA AS (NO) | 2012-10-09 | — | — | US | disclosed |
| US-20120108520-A1 | Antimicrobial Compounds and Formulations | LYTIX BIOPHARMA AS (NO) | 2012-05-03 | — | — | US | disclosed |
| US-8143211-B2 | Bioactive peptides | LYTIX BIOPHARMA AS (NO) | 2012-03-27 | — | — | US | disclosed |
| US-8048852-B2 | Antimicrobial compounds and formulations | LYTIX BIOPHARMA AS (NO) | 2011-11-01 | — | — | US | disclosed |
| EP-1263471-B1 | ANTIMICROBIAL COMPOUNDS AND FORMULATIONS | LYTIX BIOPHARMA AS (NO) | 2011-10-12 | — | — | EP | disclosed |
| EP-2338522-A1 | Antitumoural therapies | Lytix Biopharma AS (NO) | 2011-06-29 | — | — | EP | disclosed |
| EP-1109827-B1 | BIOACTIVE PEPTIDES | LYTIX BIOPHARMA AS (NO) | 2011-06-22 | — | — | EP | disclosed |
| US-20030148936-A1 | Bioactive peptides | ALPHARMA AS. | 2003-08-07 | — | — | US | disclosed |
| EP-0824962-B1 | USE OF AN OXIDATION CATALYST SYSTEM AND PROCESS FOR OXIDATION WITH THE SAME | DAICEL CHEM (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-20030022821-A1 | Bioactive peptides | ALPHARMA AS | 2003-01-30 | — | — | US | disclosed |
| EP-1258292-A1 | Oxidation catalytic system and oxidation process using same | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-11-20 | — | — | EP | disclosed |
| EP-1109831-A2 | CYCTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2001-06-27 | — | — | EP | disclosed |
| EP-1109827-A2 | BIOACTIVE PEPTIDES | ALPHARMA AS (NO) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012542-A2 | CYTOTOXIC LACTOFERRIN DERIVATIVES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2000-03-09 | — | — | WO | disclosed |
| WO-2000012541-A2 | CYTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2000-03-09 | — | — | WO | disclosed |
| US-5958821-A | EPOXIDATION OF AN ALKENE USING A CYCLIC N-HYDROXYIMIDE AND A COCATALYST OF A COMPOUND OF A GROUP 2A OR TRANSITION METAL USING OXYGEN; CATALYST SELECTIVITY; FREE OF PHOSPHO-VANADOMOLYBDIC ACID OR TETRAPHENYLPORPHYRINTOATO MANGANESE | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1999-09-28 | — | — | US | disclosed |
| EP-0824962-A1 | OXIDATION CATALYST SYSTEM AND PROCESS FOR OXIDATION WITH THE SAME | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108520-A1 | Antimicrobial Compounds and Formulations | VIP, NONO, CLPTM1 | CA1 4497/4885CA2 2554/4885CA4 3733/4885 |
| US-20030148936-A1 | Bioactive peptides | VIP, NGLY1, HM13 | CA1 1870/4885CA2 1355/4885CA4 1540/4885 |
| US-20030022821-A1 | Bioactive peptides | VIP, LITAF, LNPEP | CA1 707/4885CA2 840/4885CA4 835/4885 |
| US-20140037657-A1 | INHIBITION OF TUMOR GROWTH | STING1, VIP, MIF | CA1 1900/4885CA2 873/4885CA4 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.